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SecretionHyaluronidase1 (HYAL1) is a hydrolytic enzyme that degrades hyaluronic acid (HA) and has three
predicted N-glycosylation sites at Asn99, Asn216, and Asn350. In this report, we show the functional
signiﬁcance of N-glycosylation on HYAL1 functions. Using mass spectrometry, we demonstrated that
HYAL1 was N-glycosylated at the three asparagine residues. N-glycosylation of HYAL1 is important
for secretion of HYAL1, as demonstrated by site-directed mutation. Moreover, a defect of N-glycosyl-
ation attenuated the enzymatic activity of HYAL1. Thus, HYAL1 is N-glycosylated at the three aspar-
agine residues, and its secretion and enzymatic activity are regulated by N-glycosylation.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Protein glycosylation is important for protein functions, such as
stability, folding, and secretion [1]. N-glycosylation is a well-
known type of glycosylation in which N-glycans are directly
attached to asparagine residue in proteins. This modiﬁcation is
typically observed within the sequence motif Asn-Xaa-Ser/Thr
(Xaa represents any amino acids except Pro), and the asparagine
residue may be N-glycosylated [2,3]. Protein glycosylation takes
place enzymatically inside the lumen of the endoplasmic reticulum
(ER) [4,5]. Dolichol-phosphate precursor, composed of pre-assem-
bled oligosaccharide, is attached to certain Asn residues and is
trimmed to various types of sugar chains. More than 30 enzymes,
located in the cytosol, the ER, and the Golgi apparatus, are involved
in N-glycosylation. They are required to generate, attach, and pro-
cess the oligosaccharides; particularly, oligosaccharyltransferase
plays an essential role in synthesis of N-glycans [4–6]. Because of
the complicated structure and various patterns of N-glycans, the
functions of N-glycosylation have not been clariﬁed yet. Theaberrant condition of N-glycosylation is known to correlate with
many diseases, such as cancer and rheumatoid arthritis [7,8]. Fur-
thermore, in humans, defect in N-glycosylation induces disorders,
which are often referred to as congenital disorders of glycosylation
[9]. Therefore, further detailed investigations are required to clarify
the roles of the modiﬁcation.
Human hyaluronidase1 (HYAL1) is a member of the hyaluroni-
dase family (HYALs), which hydrolyze the b1-4 linkage between N-
acetylglucosamine and glucuronic acid of hyaluronic acid (HA)
polymers. Degradation of the extracellular matrix (ECM) by hydro-
lases, particularly matrix metalloproteinase 9, is known to associ-
ate with tumor cell growth, proliferation, and metastasis [10].
Similarly, upregulation of HYAL1 is reported to correlate with
tumor cell proliferation, migration, invasion, and angiogenesis in
many cancers [11–14]. In contrast, defects of HYAL1 are also
known to correlate with juvenile idiopathic arthritis and mucopol-
ysaccharidosis [15,16]. Thus, it is important to keep the optimal
HYAL1 activity in the tissues.
HYAL1 has 3 possible N-glycosylation consensus sequences at
Asn99, Asn216, and Asn350 [17]. A previous study predicted the pres-
ence of N-glycosylation at all asparagine residues by electron den-
sity map analysis [11]. However, there has been no direct evidence
that demonstrates the presence of N-glycosylation within HYAL1
by mass spectrometry; therefore, we undertook matrix-assisted
laser desorption ionization time of ﬂight mass spectrometry
(MALDI-TOF MS) analysis to examine whether HYAL1 is N-glycos-
ylated. Furthermore, the importance of N-glycosylation was
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evaluated by site-directed mutation (substitution of Asn to Ala)
and microplate assay and kinetic analysis [18]. We evaluated the
enzymatic activity of every N-glycosylation-defective mutant,
changing asparagine to glutamine, by using in-gel digestion assay.
In this report, we examined the presence of N-glycosylation and
its functional signiﬁcance for HYAL1. We could demonstrate that
the 3 predicted asparagine residues were N-glycosylated and
N-glycosylation played important roles in the secretion and
enzymatic activity of HYAL1. Since HYAL1 is known to correlate
with tumor malignancy, N-glycosylation of HYAL1 may be a new
target of cancer therapeutics.
2. Materials and methods
2.1. Cell culture
Human ﬁbrosarcoma HT1080 cells, purchased from Japanese
Cancer Research Resources Bank, were cultured in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM; Nissui, Tokyo, Japan), supplemented
with 10% (v/v) fetal bovine serum, 100 mg/L kanamycin, 100 units/
mL penicillin G, 600 mg/L L-glutamine, and 2.25 g/L NaHCO3, at
37 C in a humidiﬁed incubator with 5% CO2.
2.2. Construction of HYAL1 expression plasmids
Wild-type HYAL1-myc-his6 cDNA, which was subcloned into
pCI-neo vector (Promega, Madison, WI), was constructed previ-
ously [19]. We substituted the Asn99, Asn216, and Asn350 residues
in HYAL1 with Gln residues by PCR site-directed mutagenesis by
using overlap extension technique [20]. The sequences of primers
used for the mutagenesis were as follows: N99Q; 50-TGCCCCA
GCAAGCCAGCCTG-30 (forward) and 50-CAGGCTGGCTTGCTGGGGC
A-30 (reverse), N216Q; 50-CTAAGCCCCCAATACACCGG-30 (forward)
and 50-CCGGTGTATTGGGGGCTTAG-30 (reverse), and N350Q; 50-
TTCATCCTGCAAGTGACCAG-30 (forward) and 50-CTGGTCACTTGC
AGGATGAA-30 (reverse).
2.3. Establishment of HYAL1-overexpressing cell lines
A permanent cell line expressing wild-type HYAL1 (HT1080-
HYAL1-MH) was established previously [19]. Permanent cell lines
expressing mutant HYAL1-myc-his6 were established by transfect-
ing the vectors into HT1080 cells, followed by 400 lg/mL G418
(Roche Applied Sciences, Indianapolis, IN) selection. The clone cells
that expressed high levels of myc-his6-tagged HYAL1 (N99Q,
N216Q, and N350Q) were designated HT1080-HYAL1-MH/N99Q,
HT1080-HYAL1-MH/N216Q, and HT1080-HYAL1-MH/N350Q cells,
respectively. The cells transfected with pCI-neo vector were desig-
nated HT1080-neo [19].
2.4. Western blotting
To perform western blotting, we carried out previously
described methods with slight modiﬁcations [21,22]. Cells were
lysed in a lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl,
0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 1% sodium
deoxycholate, and 1 mM phenylmethylsulfonyl ﬂuoride) at 4 C
with sonication. The lysates were centrifuged at 14,000 rpm for
10 min, and the amount of protein was measured by staining with
Coomassie Brilliant Blue (CBB) G-250 (Bio-Rad Laboratories, Hercu-
les, CA). Loading buffer (350 mM Tris–HCl, pH 6.8, 30% glycerol, 6%
SDS, 0.012% bromophenol blue, and 30% 2-mercaptoethanol) was
added to each lysate, which was subsequently boiled for 3 min
and electrophoresed on SDS–polyacrylamide gels. Proteins weretransferred to PVDF membranes and immunoblotted with anti-
c-myc (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or anti-
a-tubulin (Sigma) antibodies. Detection was performed with
enhanced chemiluminescence reagent (Millipore Corporation,
Billerica, MA).
2.5. Puriﬁcation of recombinant protein from conditioned medium
To purify recombinant HYAL1 from the conditioned medium,
HT1080-HYAL1-MH cells were cultured in serum-free DMEM for
24 h, and the conditioned medium was concentrated by ultraﬁltra-
tion membrane and incubated with Ni-NTA agarose (Qiagen, Hil-
den, Germany) for 2 h at 4 C. The Ni-NTA agarose was washed 5
times with phosphate-buffered saline (PBS) and eluted with
500 mM imidazole. The obtained samples were electrophoresed
on SDS–polyacrylamide gels and stained with CBB R-250. The puri-
ﬁed proteins were used for mass spectrometry.
2.6. Mass spectrometry
Puriﬁed recombinant HYAL1 was subjected to SDS–polyacryl-
amide gel electrophoresis. After CBB staining, the bands were
excised and destained. After reduction with DTT, they were alkyl-
ated with acrylamide and treated with 0.05 mg of sequencing-
grade modiﬁed trypsin (Promega) at 37 C for 12 h in 20 mM
Tris–HCl, pH 8.0. The digests were applied to MALDI-TOF MS on
an Ultraﬂex TOF/TOF mass spectrometer (Bruker Daltonics, Bre-
men, Germany) in reﬂector mode using a-cyano-4-hydroxycin-
namic acid as the matrix.
2.7. Semi-quantitative RT-PCR
Total RNAs were extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA) as described in the manufacturer’s method, and solu-
tions containing 1 lg of total RNAs were taken for the reverse-
transcription reaction that was performed with the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster, CA), as
described previously [21,22]. The cDNA was used for PCR ampliﬁ-
cation with rTaq DNA polymerase (Takara Bio Inc., Shiga, Japan).
The number of PCR cycles for each product was determined after
conﬁrmation of the efﬁcacy of ampliﬁcation and after having
deﬁned the linear exponential portion of the ampliﬁcation. The
sequences of the primers used in the semi-quantitative RT-PCR,
the number of cycles, and the annealing temperatures were as fol-
lows: exogenous HYAL1, 50-CACGACAAACCACTTTCTGC-30 (for-
ward) and 50-GTGATGGTGATGATGCAGATCCTCTTCTGAGATGAG-30
(reverse), 25 cycles, 55 C and b-actin, 50-CTTCGAGCACGAG
ATGGCCA-30 (forward) and 50-CCAGACAGCACTGTGTTGGC-30
(reverse), 19 cycles, 58 C. PCR products were electrophoresed,
stained with ethidium bromide, and visualized with a UV
illuminator.
2.8. Detection of secreted HYAL1
HT1080-neo, HT1080-HYAL1-MH, HT1080-HYAL1-MH/N99Q,
HT1080-HYAL1-MH/N216Q, and HT1080-HYAL1-MH/N350Q cells
were cultured in serum-free DMEM for 24 h, and the conditioned
media and cell lysates were collected. Conditioned media were
concentrated by Ni-NTA agarose for 2 h at 4 C. The Ni-NTA agarose
was washed 3 times with PBS and eluted with 300 mM imidazole.
The cell lysates were prepared as described above. Loading buffer
was added to both conditioned media and cell lysates, which were
boiled for 3 min. Subsequently, the proteins were separated on
SDS–polyacrylamide gels and analyzed by immunoblot with anti-
c-myc and anti-a-tubulin antibodies.
556 Y. Goto et al. / FEBS Open Bio 4 (2014) 554–5592.9. Measurement of hyaluronidase activity
To measure HYAL1 activity by in-gel digestion assay, we carried
out the experiment using previously reported methods [18,23].
HT1080-neo, HT1080-HYAL1-MH, HT1080-HYAL1-MH/N99Q,
HT1080-HYAL1-MH/N216Q, and HT1080-HYAL1-MH/N350Q cells
were lysed in binding buffer (20 mM Tris–HCl, pH 7.5, 500 mM
NaCl, 20 mM imidazole) and concentrated by using Ni-NTA aga-
rose. Ni-NTA-bound proteins were eluted, and the samples were
electrophoresed on an SDS–polyacrylamide gel containing rooster
comb HA (0.2 mg/mL; Sigma) at 4 C. The gel was washed twice
with SDS extraction buffer (50 mM Tris–HCl, pH 7.5, 0.1 M NaCl,
2.5% Triton X-100) for 1 h and incubated in assay buffer (50 mM
sodium formate, pH 4.0, 150 mMNaCl) at 37 C for 24 h. After incu-
bation, the gel was stained with 0.5% alcian blue (Sigma) contain-
ing 10% acetic acid and 20% ethanol solution for 2 h and destained
with 25% methanol and 7.5% acetic acid solution. HYAL1 activity
can be observed as a transparent band in the blue pigment
background.
3. Results
3.1. HYAL1 was N-glycosylated
Human HYAL1 contains 3 possible N-glycosylation consensus
sequences at the Asn99, Asn216, and Asn350 residues (Fig. 1A).
Tunicamycin (TM) blocks the synthesis of all N-linked glycopro-
teins; therefore, treatment of cells with TM is predicted to cause
N-glycosylated proteins to have a more rapidly migrating form
compared with untreated cells. We treated HT1080-HYAL1-MH
cells with TM, which were established previously [19], and as a
result, 10 lg/mL TM treatment resulted in a size reduction of
HYAL1-MH (Fig. 1B). These data suggested that HYAL1 was N-
glycosylated.
3.2. HYAL1 is N-glycosylated at 3 predicted sites revealed by MALDI-
TOF MS analysis
We undertook MALDI-TOF MS analysis to determine whether
HYAL1 is N-glycosylated or not [24]. To obtain recombinant HYAL1
protein, we puriﬁed HYAL1 protein from conditioned medium of1 2122
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Fig. 1. N-glycosylation of HYAL1. (A) The locations of 3 putative N-glycosylation sites (A
signal peptide. The active site of HYAL1 (Glu131) is indicated by an asterisk. (B) Cells were
cell lysate was electrophoresed and immunoblotted with the indicated antibodies.HT1080-HYAL1-MH cells by using Ni-NTA agarose (Fig. 2A). Puri-
ﬁed HYAL1 was digested with trypsin and treated with or without
PNGase F, which can cleave between the innermost GlcNAc and
asparagine residues of N-linked glycoproteins, thereby converting
N-glycosylated Asn to Asp. A resulting peptide treated with PNGase
F was observed at the expected position (m/z 4431.8), at which
Asn99 was replaced with Asp99, suggesting that HYAL1 is N-glycos-
ylated at Asn99 (Fig. 2B). Similarly, MALDI TOF-MS analysis demon-
strated that the peptides that were converted from Asn216 and
Asn350 to Asp residues after treatment with PNGase F were
observed at the expected position (m/z 3581.0 and 3397.9), respec-
tively (Fig. 2C and D). These results indicated that HYAL1 was
N-glycosylated at 3 predicted N-glycosylation consensus
sequences: Asn99, Asn216, and Asn350.
3.3. N-glycosylation is essential for HYAL1 secretion
Since we demonstrated that HYAL1 was N-glycosylated at
Asn99, Asn216, and Asn350, we tried to evaluate the roles of N-glyco-
sylation in HYAL1 functions by using mutant forms of the protein,
replacing asparagine residues with glutamine residues. Therefore,
we established HT1080-HYAL1-MH/N99Q, HT1080-HYAL1-MH/
N216Q, and HT1080-HYAL1-MH/N350Q cell lines. The electropho-
retic migrations of the mutant HYAL1 cell lysates were slightly fas-
ter than that from HT1080-HYAL1-MH (Fig. 3A). Equal amounts of
exogenous HYAL1 in the stable cell lines were conﬁrmed by semi-
quantitative RT-PCR (Fig. 3B). It suggests that inhibition of N-glyco-
sylation by site-directed mutation induces size reduction.
Since the secretion of HYAL1 by tumor cells has been shown to
correlate with tumor malignancy [25], we evaluated the effect of
N-glycosylation onHYAL1 secretion by comparingwild-typeHYAL1
with each N-glycosylation-defective HYAL1 mutant. As a result,
secretion levels of N99Q, N216Q, and N350Q mutant HYAL1-MH
were eliminated, although wild-type HYAL1 was secreted into con-
ditioned medium (Fig. 3C). It suggested that a defect of in each N-
glycosylation site within HYAL1 inhibited its secretion.
3.4. N-glycosylation is necessary for enzymatic activity of HYAL1
We examined the effects of N-glycosylation on HYAL1 enzy-
matic activity assessed by in-gel digestion assay [18,23]. We435
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lysates by using Ni-NTA agarose. The amount of obtained protein
level was almost equivalent, conﬁrmed by western blotting
(Fig. 4, lower). In the same condition, we evaluated the enzymatic
activity of each HYAL1 protein. Wild-type HYAL1 contained abun-
dant enzymatic activity, but the N99Q mutant protein eliminated
enzymatic activity (Fig. 4, upper). Moreover, the N216Q and
N350Q HYAL1 mutants also decreased their enzymatic activities
compared with wild-type HYAL1. These results demonstrated that
N-glycosylation, especially Asn99, plays an essential role in HYAL1
enzymatic activity.
4. Discussion
In this report, we demonstrated that HYAL1 was N-glycosylated
at Asn99, Asn216, and Asn350, revealed by mass spectrometry
(Fig. 2). Protein N-glycosylation, the attachment of N-glycans to
Asn, is known to change protein conformation and protein polarity,
which is predicted to change many functions [1]. Our results
showed that each N-glycosylation-defective mutant decreased its
secretion and enzymatic activity (Figs. 3C and 4). It is probably
due to conformational changes of HYAL1. Moreover, decrease of
protein stability and/or defect of the recognition step of protein
transport are possible reasons for the decrease of secretion. In fact,
the protein level of each N-glycosylation-defective mutant HYAL1
in cells was also decreased compared with wild-type
HYAL1 (Fig. 3C). Therefore, protein stability was decreased, and
HYAL1 was probably degraded by ER-associated degradation,
because the total amounts of HYAL1 protein—intracellular and
secreted HYAL1—were decreased in each N-glycosylation-defective
mutant HYAL1.
It has been reported that ER stress inhibited secretion of the
proteins [26]. To address whether suppression of mutant form-
HYAL1 secretion is due to the induction of ER stress, we examined
the effect of ER stress inducer on the secretion. Treatment with DTT
of the cells induced Bip expression, a well-known marker of ER
stress induction, and secretion level of HYAL1 was reduced (data
not shown). However, expression levels of Bip were not changed
in mutant form-HYAL1 expressing cells (N99Q, N216Q and
N350Q) compared with wild-type HYAL1 expressing cells and con-
trol cells (data not shown), indicating that mutant HYAL1 did not
induce ER stress. These results suggested that suppression of
mutant form-HYAL1 secretion was not due to the ER stress induc-
tion, and that defect of each three N-glycosylation might be chan-
ged the HYAL1 conformation not to be secreted. Taken together,(kDa)
IB
Anti-c-myc
Ab
57
43
Stained with
alcian blue
HYAL1-MH
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Fig. 4. N-glycosylation controls enzymatic activity of HYAL1. Exponentially grow-
ing neo, wt, N99Q, N216Q, and N350Q cells were lysed, and cell lysates were
incubated with Ni-NTA agarose for 2 h. Ni-NTA-bound HYAL1 was washed and
eluted with 500 mM imidazole. The amount of each protein was evaluated by
western blotting with anti-c-myc antibody (lower). Equal amounts of samples were
electrophoresed on an SDS polyacrylamide gel containing 0.2 mg/mL HA. The gel
was incubated at 37 C for 24 h after extraction of SDS and stained with alcian blue
(upper). (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)our results revealed that N-glycosylation of HYAL1 affects its func-
tions, such as enzymatic activity and secretion.
A previous study suggested the presence of N-glycosylation at 3
predicted asparagine residues, revealed by electron density map
analysis [11]. On the other hand, we directly demonstrated that
N-glycans were attached to Asn99, Asn216, and Asn350 revealed by
mass spectrometry. Previous studies also suggested the impor-
tance of N-glycosylation for the enzymatic activity of HYAL1,
revealed by microplate assay and kinetic analysis [18,27]. How-
ever, these reports did not evaluate the effect of N-glycosylation
at Asn99 and evaluated it by using a mutant that was changed from
Asn to Ala. In contrast, we showed that N-glycosylation of HYAL1 at
3 Asn, especially Asn99, was important for enzymatic activity by
using in-gel digestion assay (Fig. 4). Our results are consistent with
a previous report and furthermore show novelty. Intracellular
HYAL1 and secreted HYAL1 from tumor cells are known to
correlate with tumor malignancy [25]. Thus, the secretion of every
N-glycosylation-defective mutant HYAL1 was eliminated although
wild-type HYAL1 was secreted (Fig. 3C), suggesting the signiﬁcance
of N-glycosylation for the behavior of malignant tumors. These
results indicated that N-glycosylation is important for enzymatic
activity of HYAL1 and its secretion. Therefore, inhibition of N-
glycosylation will lead to regulation of malignant tumor behavior
caused by overexpression of HYAL1.
In conclusion, we demonstrated that HYAL1 is N-glycosylated at
3 predicted N-glycosylation consensus sequences and revealed its
roles in N-glycosylation for secretion and enzymatic activity of
HYAL1. Since HYAL1 is known to promote tumor growth and
metastasis, inhibition of HYAL1 N-glycosylation can be a new tar-
get for cancer therapeutics.
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